Steven L. Hoerter - 21 Mar 2022 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role: President and CEO, Director
Signature: /s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol: DCPH
Transactions as of: 21 Mar 2022
Transactions value $: -$28,697
Form type: 4
Filing time: 23 Mar 2022, 16:15:25 UTC
Previous filing: 20 Jan 2022
Next filing: 17 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DCPH	Common Stock	Tax liability	-$28.7K	-3.15K	-7.74%	$9.11	37.5K	21 Mar 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 18, 2019, the Reporting Person was granted 30,000 Restricted Stock Units ("RSUs") which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021 to cover tax obligations.

Content

On March 18, 2019, the Reporting Person was granted 30,000 Restricted Stock Units ("RSUs") which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021 to cover tax obligations.